An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects

Trial Profile

An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs Bosutinib (Primary) ; Aprepitant
  • Indications Chronic myeloid leukaemia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Oct 2016 Results published in the European Journal of Clinical Pharmacology
    • 23 Jun 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top